Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-α antagonists

Purpose of reviewSeveral biological agents have been introduced into the drug market and more are emerging. Adverse reactions to these agents have recently been classified into five different subtypes. Some of these reactions are frequent but without consequences for the patients. Others are less frequent but potentially life-threatening, and they include allergic reactions. Recent findingsHypersensitivity reactions are well described adverse drug reactions, corresponding to the ß-type of the newly proposed classification of adverse reactions induced by biological agents. We focus our search on tumor necrosis factor-α antagonists, as they represent a dramatic improvement in the therapy of both rheumatic and inflammatory bowel diseases and because adverse reactions have been closely scrutinized. We also add cases from our own experience. We found very few properly documented allergic reactions. SummaryHypersensitivity reactions to tumor necrosis factor-α antagonists are not rare. Whether these manifestations have to be considered type β or type γ reactions is still a matter of debate. There is a need for allergological tests in vivo and in vitro.

[1]  Issa J Dahabreh,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. , 2008, Clinical therapeutics.

[2]  A. Taher,et al.  Recurrent skin reaction secondary to darbepoetin alfa for two months in a patient with chronic lymphocytic leukemia , 2007, American journal of hematology.

[3]  C. Fernandes,et al.  Anaphylactoid reaction to recombinant tissue plasminogen activator. , 2007, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[4]  E. Savilahti,et al.  Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease , 2007, Acta paediatrica.

[5]  P. Peloso,et al.  The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.

[6]  T. Jansen,et al.  Anaphylactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor? , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[7]  L. Kappos,et al.  Infusion-related hypersensitivity reactions during natalizumab treatment , 2006, Neurology.

[8]  L. Salvagno,et al.  Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  B. Wallaert,et al.  Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions , 2006, Alimentary pharmacology & therapeutics.

[10]  B. Chipps Systemic reaction to omalizumab. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[11]  L. Truedsson,et al.  - 1-Predictors of infusion reactions during infliximab treatment in patients with arthritis , 2006 .

[12]  J. Ménard,et al.  Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. , 2006, The Journal of rheumatology.

[13]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[14]  B. Dijkmans,et al.  Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[15]  S. Hsu,et al.  Adalimumab-induced urticaria. , 2006, Dermatology online journal.

[16]  P. Kouides,et al.  Rituximab-induced leukocytoclastic vasculitis: a case report. , 2006, Archives of dermatology.

[17]  T. Horn,et al.  Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. , 2006, Archives of dermatology.

[18]  B. Thiers Adalimumab for the Treatment of Patients With Moderately to Severely Active Psoriatic Arthritis: Results of a Double-blind, Randomized, Placebo-controlled TrialMease PJ, for the Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group (Seattle Rheumatology Associates; et al) Arthritis Rheum , 2006 .

[19]  G. Wall,et al.  Possible drug rash with eosinophilia and systemic symptoms syndrome after exposure to epoetin alfa. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[20]  P. Milkiewicz,et al.  Diffuse skin reaction in patient with hepatitis B, treated with two different formulations of pegylated interferon. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[21]  J. Sany,et al.  Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis , 2005, Annals of the rheumatic diseases.

[22]  D. Gladman,et al.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[23]  A. Bennett,et al.  Adalimumab-induced asthma. , 2005, Rheumatology.

[24]  M. Fernández-Figueras,et al.  Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients , 2005, The British journal of dermatology.

[25]  C. Kittas,et al.  Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. , 2005, Arthritis and rheumatism.

[26]  P. Sørensen,et al.  Appearance and disappearance of neutralizing antibodies during interferon-beta therapy , 2005, Neurology.

[27]  L. Mayer,et al.  Monoclonal antibodies, immunogenicity, and associated infusion reactions. , 2005, The Mount Sinai journal of medicine, New York.

[28]  A. Sanyal,et al.  Antibody-Mediated Pure Red Cell Aplasia Due to Epoetin Alfa During Antiviral Therapy of Chronic Hepatitis C , 2005, The American Journal of Gastroenterology.

[29]  R. Baldassano,et al.  Premedication and Infusion Reactions With Infliximab: Results From a Pediatric Inflammatory Bowel Disease Consortium , 2005, Inflammatory bowel diseases.

[30]  A. Tonnel,et al.  Accoutumance médicamenteuse à l'infliximab dans la maladie de Crohn , 2005 .

[31]  M. Scheinberg,et al.  Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. , 2005, Arthritis and rheumatism.

[32]  R. Priori,et al.  Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. , 2005, Rheumatology.

[33]  A. H. Diwan,et al.  Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma , 2005, Leukemia & lymphoma.

[34]  B. Wallaert,et al.  [Desensitisation to infliximab in patients with Crohn's disease]. , 2005, Revue des maladies respiratoires.

[35]  M. Chávez-López,et al.  Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. , 2005, Allergologia et immunopathologia.

[36]  C. Rosé,et al.  Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. , 2004, The Journal of rheumatology.

[37]  S. Hanauer,et al.  An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Prior Loss of Response or Intolerance to Infliximab for Crohn's Disease , 2004, American Journal of Gastroenterology.

[38]  J. Guilhou,et al.  Psoriatic lesions induced by antitumour necrosis factor‐α treatment: two cases , 2004, The British journal of dermatology.

[39]  S. Targan,et al.  A Pilot Study of Adalimumab in Infliximab-Allergic Patients , 2004, Inflammatory bowel diseases.

[40]  T. Giese,et al.  Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. , 2004, European journal of gastroenterology & hepatology.

[41]  R. Aster,et al.  Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug , 2004, Journal of thrombosis and haemostasis : JTH.

[42]  R. Baldassano,et al.  Human Antichimeric Antibody in Children and Young Adults with Inflammatory Bowel Disease Receiving Infliximab , 2004, Journal of pediatric gastroenterology and nutrition.

[43]  P. Lipsky,et al.  Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. , 2004, Arthritis and rheumatism.

[44]  P. Rutgeerts,et al.  Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. , 2004, Gastroenterology.

[45]  J. Kremer,et al.  Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[46]  J. Dutcher,et al.  Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin Lymphoma , 2004, Leukemia & lymphoma.

[47]  A. Zinsmeister,et al.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. , 2004, Gastroenterology.

[48]  B. Hellerstedt,et al.  Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  S. Helfgott,et al.  Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? , 2003, The Journal of rheumatology.

[50]  P. Emery,et al.  Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. , 2003, The Journal of rheumatology.

[51]  A. Erhardt,et al.  Arzneimittelexanthem durch pegyliertes Interferon-α2b , 2003, Der Hautarzt.

[52]  E. Haddad,et al.  Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti–interleukin-2 receptor monoclonal antibody basiliximab , 2003, Transplantation.

[53]  W. Berger,et al.  Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[54]  K. McGrath,et al.  Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. , 2003, Allergy and asthma proceedings.

[55]  D. McGill,et al.  Severe hypotension complicating primary angioplasty: allergy to abciximab , 2003, Allergy.

[56]  S. Plevy,et al.  The Incidence and Management of Infusion Reactions to Infliximab: A Large Center Experience , 2003, American Journal of Gastroenterology.

[57]  W. Tyler,et al.  Worsening injection site reactions with continued use of etanercept. , 2003, Journal of drugs in dermatology : JDD.

[58]  M. Peppercorn,et al.  Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. , 2003, Gastroenterology.

[59]  K. Tada,et al.  Severe infusion reaction induced by trastuzumab: A case report , 2003, Breast cancer.

[60]  A. Domm A patient's reaction to infliximab. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[61]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[62]  C. Garcia,et al.  Anaphylactic shock after retreatment with basiliximab. , 2003, Transplantation proceedings.

[63]  R. Schneider,et al.  Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. , 2003, The Journal of rheumatology.

[64]  B. Korelitz,et al.  Red man syndrome and infliximab. , 2003, Journal of clinical gastroenterology.

[65]  W. Crandall,et al.  Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model , 2003, Alimentary pharmacology & therapeutics.

[66]  E. Jourdan,et al.  Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative Disorder , 2003, Leukemia & lymphoma.

[67]  A. Erhardt,et al.  [Drug-induced exanthema caused by pegylated interferon-alpha 2b]. , 2003, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[68]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[69]  K. Woodside,et al.  Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody , 2002, Transplantation.

[70]  G. Mead,et al.  Stevens-Johnson syndrome after treatment with rituximab. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[71]  S. Hanauer,et al.  Infliximab in the treatment of Crohn's disease: a user's guide for clinicians , 2002, American Journal of Gastroenterology.

[72]  Jon E. Stahlman,et al.  Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin). , 2002, The Journal of allergy and clinical immunology.

[73]  I. Betlloch,et al.  Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. , 2002, Archives of dermatology.

[74]  K. Eckardt,et al.  Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. , 2002, Journal of the American Society of Nephrology : JASN.

[75]  Y. Herishanu Rituximab‐induced serum sickness , 2002, American journal of hematology.

[76]  E. Matteson,et al.  Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[77]  S. Kugathasan,et al.  Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction , 2002, American Journal of Gastroenterology.

[78]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[79]  M. Castro,et al.  Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease. , 2002, The Journal of pediatrics.

[80]  John A. Godfrey,et al.  Delayed Hypersensitivity Reaction and Acute Respiratory Distress Syndrome Following Infliximab Infusion , 2002, Inflammatory bowel diseases.

[81]  D. Palisaitis,et al.  Potential Anaphylactic Shock with Abciximab Readministration , 2002, Pharmacotherapy.

[82]  D. Moneret-vautrin,et al.  T cell mediated allergy to abciximab , 2002, Allergy.

[83]  M. O'connor,et al.  Anaphylaxis-like reaction to infliximab in a patient with Crohn's disease. , 2002, Digestive diseases and sciences.

[84]  R. Quinet,et al.  Etanercept and infliximab associated with cutaneous vasculitis. , 2002, Rheumatology.

[85]  J. Rossi,et al.  Rituximab-Induced Vasculitis , 2001, Dermatology.

[86]  C. Pechlaner,et al.  Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase. , 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[87]  L. Grammer,et al.  Hypersensitivity to IFN‐α , 2001 .

[88]  A. Levinson,et al.  Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. , 2001, Archives of dermatology.

[89]  M. Mannik,et al.  Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). , 2001, Arthritis and rheumatism.

[90]  C. Ritchlin,et al.  Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. , 2001, Archives of dermatology.

[91]  D. L. Brown,et al.  An urticarial IgE-mediated reaction to interferon β-1b , 2001, Neurology.

[92]  L. Putte,et al.  Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor alpha blocking treatment. , 2001 .

[93]  S. Kugathasan,et al.  Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. , 2001, Inflammatory bowel diseases.

[94]  D. L. Brown,et al.  An urticarial IgE-mediated reaction to interferon beta-1b. , 2001, Neurology.

[95]  S. Hanauer,et al.  Infliximab in Crohn's disease: first anniversary clinical experience , 2000, American Journal of Gastroenterology.

[96]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[97]  T. Schaible Long term safety of infliximab. , 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[98]  A. Özden,et al.  Severe anaphylactic reaction to infliximab: report of a case , 2000, American Journal of Gastroenterology.

[99]  J. Hyams Use of Infliximab in the Treatment of Crohn's Disease in Children and Adolescents , 2000, The Journal of pediatrics.

[100]  C. Possidente,et al.  Anaphylactoid Reaction to Muromonab‐CD3 in a Pediatric Renal Transplant Recipient , 2000, Pharmacotherapy.

[101]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[102]  T. Nichols,et al.  Possible anaphylactic reaction to abciximab , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[103]  W. Heiss,et al.  Evidence of anaphylaxy after alteplase infusion. , 1999, Stroke.

[104]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[105]  H. Kaminski Achalasia and myasthenia gravis in a patient with thymoma , 1999, Neurology.

[106]  L. Ostrosky-Zeichner,et al.  Severe anaphylaxis with recombinant interferon beta , 1999, Neurology.

[107]  D. Furst,et al.  Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. , 1999, Annals of internal medicine.

[108]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[109]  L. Moscinski,et al.  Type III hypersensitivity reaction with the use of interferon‐α , 1997, American journal of hematology.

[110]  J. C. Orta Cuevas,et al.  Probable hypersensitivity reaction to filgrastim. , 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[111]  R. Weiss,et al.  Immediate hypersensitivity to human recombinant granulocyte-macrophage colony-stimulating factor associated with a positive prick skin test reaction. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[112]  D. Abramowicz,et al.  The IgE humoral response in OKT3-treated patients. Incidence and fine specificity. , 1996, Transplantation.

[113]  B. Taillan,et al.  [No cross hypersensitivity between molgramostim and filgrastime: apropos of a case]. , 1995, Therapie.

[114]  W. Paul,et al.  CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3 , 1994, The Journal of experimental medicine.

[115]  D. Mccluskey,et al.  Anaphylactoid reaction after injection of alteplase , 1993, The Lancet.

[116]  C. King,et al.  Generalized eczematous reaction to erythropoietin , 1993, Contact dermatitis.

[117]  M. Turner,et al.  Late reactions during initial OKT-3 treatment , 1993 .

[118]  D. Abramowicz,et al.  Anaphylactic shock after retreatment with OKT3 monoclonal antibody. , 1992, The New England journal of medicine.

[119]  D. Massel,et al.  Anaphylactoid reaction during an infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction. , 1991, The Canadian journal of cardiology.

[120]  A. S. Cheung,et al.  Anaphylactic hypersensitivity reaction after repeat OKT3 treatment , 1991, The Lancet.

[121]  J. Georgitis,et al.  Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection. , 1991, Annals of allergy.

[122]  F. Finkelman,et al.  Anti-CD3 antibody induces rapid expression of cytokine genes in vivo. , 1990, Journal of immunology.

[123]  D. Abramowicz,et al.  Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. , 1990, Journal of immunology.